Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 17 Breast Neoplasms 6 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 4 Fallopian Tube Neoplasms 4 Sarcoma 3 Neoplasms 3 Solid Tumor 2 Small Cell Lung Carcinoma 2 Recurrence 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Breast Cancer Metastatic 2 Advanced Solid Tumors 2 Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 SCLC, Extensive Stage 1 Platinum-sensitive Relapsed Ovarian Cancer 1 Osteosarcoma 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1 Metastatic Castration Resistant Prostate Cancer 1 Kenny-Caffey syndrome, Type 1 1 Her-2 Negative Breast Cancer 1 Glioblastoma 1 Fludzoparib" and Anti-angiogenic 1 Female Breast Cancer Patients 1

Interventions

Nivolumab 20 Ipilimumab 10 Surveys and Questionnaires 7 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Interviews as Topic 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × fluzoparib × Clear all

NCT04193319 2019-12-10

Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡